文献速递青光眼

他汀类药物使用与青光眼结构性和功能性丢失速率之间的关联

Association between statin use and rates of structural and functional loss in glaucoma.
PubMed 文献 · Br J Ophthalmol · 2022-05-10

这项回顾性队列研究纳入杜克青光眼登记库中原发性开角型青光眼和青光眼疑似患者3007只眼(1978例患者),平均随访4.7±2.0年,比较使用他汀组与对照组在标准自动视野计平均偏差和视网膜神经纤维层厚度变化速率上的差异。结果显示两组在平均偏差(-0.07±0.16 dB/年 vs -0.07±0.15 dB/年,p=0.873)和视网膜神经纤维层厚度(-0.70±0.60 µm/年 vs -0.70±0.61 µm/年,p=0.923)变化速率上无差异,他汀使用时长亦无显著关联。

要点

  • 他汀使用组与对照组在视野平均偏差变化速率上无显著差异(p=0.873)。
  • 他汀使用组与对照组在视网膜神经纤维层厚度变化速率上无显著差异(p=0.923)。
  • 他汀使用时长与视野平均偏差或视网膜神经纤维层厚度变化速率无显著关联。

核心结论

  • 未发现他汀使用或他汀使用时长与青光眼或青光眼疑似患者的结构性和功能性变化速率之间存在统计学显著关联。

研究设计与样本

  • 回顾性队列研究,纳入杜克青光眼登记库中原发性开角型青光眼和青光眼疑似患者,共3007只眼(1978例患者),平均随访4.7±2.0年。
  • 根据他汀使用史分组,其中775例受试者(1179只眼)有他汀使用史。
  • 使用线性混合模型估算标准自动视野计平均偏差和谱域光学相干断层扫描视网膜神经纤维层厚度随时间的变化速率,并比较他汀组与对照组。
  • 分析调整了年龄、性别、种族、眼压和随访时间等潜在混杂因素。
  • 青光眼患者与疑似患者分别进行分析。

主要发现

  • 共纳入10049次标准自动视野计检查和14198次谱域光学相干断层扫描检查。
  • 他汀组与对照组平均偏差变化速率分别为-0.07±0.16 dB/年和-0.07±0.15 dB/年(p=0.873),无差异。
  • 他汀组与对照组视网膜神经纤维层厚度变化速率分别为-0.70±0.60 µm/年和-0.70±0.61 µm/年(p=0.923),无差异。
  • 多变量模型控制潜在混杂因素后,他汀使用时长与平均偏差或视网膜神经纤维层厚度变化速率无显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To evaluate the association between statin use and rates of standard automated perimetry (SAP) and retinal nerve fibre layer (RNFL) change in patients with glaucoma and glaucoma suspects. METHODS: This retrospective cohort study included subjects from the Duke Glaucoma Registry with primary open-angle glaucoma and glaucoma suspects. Subjects were assigned to groups according to history of statin use. Rates of change in SAP mean deviation (MD) and spectral-domain optical coherence tomography (SD OCT) RNFL thickness over time were estimated using linear mixed models and compared in the statin versus control groups. The effect of duration of statin use was also assessed. Patients with glaucoma versus suspects were analysed separately. Analyses were adjusted for potential confounding factors of age, gender, race, intraocular pressure and follow-up time. RESULTS: The study included 10 049 SAP tests and 14 198 SD OCT tests from 3007 eyes (1978 patients) followed for an average of 4.7±2.0 years. Of these, 775 subjects (1179 eyes) had a history of statin use. No difference in rates of change was seen between the statin versus control groups for MD (-0.07±0.16 dB/year vs -0.07±0.15 dB/year; p=0.873, respectively) or RNFL thickness (-0.70±0.60 µm/year vs -0.70±0.61 µm/year; p=0.923, respectively). Multivariable models controlling for potential confounders showed no significant association between duration of statin use and rates of MD or RNFL thickness change. CONCLUSIONS: We did not find a statistically significant association between statin use or duration of statin use and rates of structural and functional change in those with glaucoma or glaucoma suspects.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kang JM, Jammal AA, Medeiros FA, et al. Association between statin use and rates of structural and functional loss in glaucoma. Br J Ophthalmol. 2022. PMID: 35537803. doi:10.1136/bjophthalmol-2021-320734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。